Home/Filings/4/0001062993-22-016557
4//SEC Filing

Rosenberger Brian 4

Accession 0001062993-22-016557

CIK 0001621443other

Filed

Jul 19, 8:00 PM ET

Accepted

Jul 20, 4:06 PM ET

Size

1.8 MB

Accession

0001062993-22-016557

Insider Transaction Report

Form 4
Period: 2022-07-18
Rosenberger Brian
VP, Commercial
Transactions
  • Sale

    Common Stock

    2022-07-19$1.10/sh4,289$4,718107,511 total
  • Award

    Common Stock

    2022-07-18+14,800111,800 total
Footnotes (2)
  • [F1]On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 14,800 performance-based restricted stock awards granted in a prior year.
  • [F2]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.

Issuer

Zynerba Pharmaceuticals, Inc.

CIK 0001621443

Entity typeother

Related Parties

1
  • filerCIK 0001695788

Filing Metadata

Form type
4
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 4:06 PM ET
Size
1.8 MB